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Abstract: The COVID-19 pandemic has escalated the occurrence of hypoxia including thrombotic
stroke worldwide, for which nitric oxide (NO) therapy seems very promising and translatable.
Therefore, various modes/routes of NO-delivery are now being tested in different clinical trials for
safer, faster, and more effective interventions against ischemic insults. Intravenous (IV) infusion of
S-Nitrosoglutathione (GSNO), the major endogenous molecular pool of NO, has been reported to
protect against mechanical cerebral ischemia-reperfusion (IR); however, it has been never tested in
any kind of “clinically” relevant thromboembolic stroke models with or without comorbidities and
in combination with the thrombolytic reperfusion therapy. Moreover, “IV-effects” of higher dose of
GSNO following IR-injury have been contradicted to augment stroke injury. Herein, we tested the
hypothesis that nebulization of low-dose GSNO will not alter blood pressure (BP) and will mitigate
stroke injury in diabetic mice via enhanced cerebral blood flow (CBF) and brain tissue oxygenation
(PbtO2). GSNO-nebulization (200 µg/kgbwt) did not alter BP, but augmented the restoration of CBF,
improved behavioral outcomes and reduced stroke injury. Moreover, GSNO-nebulization increased
early reoxygenation of brain tissue/PbtO2 as measured at 6.5 h post-stroke following thrombolytic
reperfusion, and enervated unwanted effects of late thrombolysis in diabetic stroke. We conclude
that the GSNO-nebulization is safe and effective for enhancing collateral microvascular perfusion in
the early hours following stroke. Hence, nebulized-GSNO therapy has the potential to be developed
and translated into an affordable field therapy against ischemic events including strokes, particularly
in developing countries with limited healthcare infrastructure.
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1. Introduction
Stroke primarily happens due to a thromboembolic occlusion (~87% strokes) resulting
in reduced cerebral blood flow (CBF) and decreased brain tissue oxygenation (PbtO2) [1].
More than 13 million strokes per year occur worldwide, placing stroke among the leading
causes of adult mortality and disability (http://world-stroke.org, accessed on 31 August
2021) [2]. The Kingdom of Saudi Arabia (KSA) is a high-income country yet has limited
healthcare infrastructures [3]; hence, the escalating rate of stroke in the KSA is frightening,
and now recognized as the second major contributor to adult mortality in the nation [3].
Advancements in stroke management made faster interventions feasible in remote settings,
thereby reducing the mortality but the risk of increasing number of disabled survivors
remains associated [3]. Since the microvascular reperfusion and restoration of PbtO2
remains the only proven therapeutic strategy in stroke, the development of field therapies,
which can be conveniently administered to the stroke victims in the primary care centers,
during transportation and in the emergency departments (EDs), is essentially needed
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for faster interventions. Moreover, the development of adjunct therapies which will not
contradict with the FDA-approved reperfusion therapies but will enhance benefits of
reperfusion, is also highly encouraged [4].
Enhanced sedentary lifestyle in the KSA now has collectively invoked the uprise
of various metabo-physiological disorders, increasing the risk of stroke [3,5]. Among
the Arabic-speaking regions, the KSA has the most elevated rate of increase in diabetes.
Of note, the American Heart Association (AHA) recently estimated ~2× higher risk of
stroke among diabetic individuals compared to non-diabetics (https://www.stroke.org/
en/about-stroke/stroke-risk-factors/diabetes-and-stroke-prevention, accessed on 31 August 2021). Among these metabo-physiological comorbidities including diabetes, endothelial dysfunction resulting in poor level of vasculo-protective nitric oxide (NO) remains a
common pathophysiology [6]. As such, endothelial dysfunction is widely recognized as
one of the significant reasons for impaired neurovascular protection and neurorestoration
after stroke [7].
The translation of NO-therapy has been always an interesting therapeutic domain
for vascular protection in ischemic stroke [8], yet its success has remained limited due to
challenges associated with the delivery of NO [7,9]; otherwise, the risk of blood pressure
(BP) lowering and subsequent hemorrhagic transformation (HT) remains warranted in
stroke. Despite this, following a worldwide increase in the incidences of hypoxia and
stroke due to the COVID-19 pandemic, several clinical trials have been initiated recently to
test and enhance the safety and efficacy of NO-delivery via different modes and routes of
administration (NCT04476992, NCT04383002, NCT04305457, NCT04337918, NCT04601077).
Thus, developing the therapeutic strategy to translate an endogenous NO-carrier/donor is
an appealing avenue in ischemic events including stroke [8].
S-Nitrosoglutathione (GSNO), a highly soluble small molecule major endogenous
carrier/donor of NO, has shown benefits in mechanically occluded/reperfused stroke
models [10,11]. GSNO-therapy also reduced embolization in human patients [12], attenuated secondary ischemia after subarachnoid hemorrhage (SAH) [13], and, of particular
interest, induced hypoxic vasodilation to enhance CBF in rodents [10,11,14]. However, a
risk of augmented stroke injury remains intact with the higher dose of exogenous GSNOtherapy when administered “intravenously” (IV) [15]. Therefore, prior to embarking on
a possible clinical trial in future, it is critical to re-evaluate and develop alternative approaches in a preclinical setting to safely administer GSNO-therapy in stroke. Furthermore,
despite promising effects in healthy animals [10,11], GSNO remains untested in any kind
of clinically relevant animal models of thromboembolic stroke with comorbidity which can
facilitate its preclinical validation with IV-thrombolytic (IVT) therapy, the gold standard
treatment among the two FDA-approved reperfusion therapies in stroke.
In the present work, we have adopted a simple approach for the preclinical translation
and validation of GSNO-therapy with or without IVT in a thrombotic stroke model in
diabetic mice, a preclinical setting representing the diabetic stroke patients who are often
least benefitted from the IVT-therapy due to higher risk of HT. We tested the hypothesis that
nebulization of low-dose GSNO following thrombotic stroke in diabetic mice will mitigate
stroke injury, improve behavioral outcomes, and enhance the benefits of thrombolytic
reperfusion via improved PbtO2.
2. Materials and Methods
2.1. Animals and Experimental Approach
In-house bred male C57/B6 were used in accordance with the approved animal protocol by the ethical committee of Center of Excellence in Genomic Medicine Research
(CEGMR) at King Abdulaziz University in accordance with the guidelines of National
Bioethical Committee of Saudi Arabia (NACSA). All mice were subjected to streptozotocin (STZ) induced type-I diabetes for 3 weeks prior to stroke injury and GSNO nebulization. This diabetic stroke model has been validated to test therapies in a setting of
post-thrombolysis risk of HT [16,17]. In Experiment I (n = 7 mice/set), we determined the
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baseline BP with vehicle control treatments followed by either IV-GSNO (1-mg per kg body
weight (/kgbwt)) or GSNO-Nebulization (200 µg/kgbwt) effects on BP. In Experiment II
(n = 12 mice/group; 2 groups; Vehicle control (+Veh) vs. GSNO treated (+GSNO)), we
tested the efficacy of low-dose GSNO nebulization following thrombotic stroke on CBF,
behavioral outcomes and stroke injury size (24 h and 48 h post-stroke outcomes, respectively). In Experiment III (n = 10 mice/group; 2 groups; +Veh vs. +GSNO), we tested
GSNO-nebulization with late-IVT therapy (given at 3.5 h post-stroke) to determine PbtO2
at 6.5 h post-stroke. In Experiment IV (n = 20 mice/group; 2 groups; +Veh vs. +GSNO),
we tested the effect of GSNO-nebulization in combination with late-IVT on behavioral
outcomes, blood-brain barrier (BBB) and HT (24 h endpoint).
2.2. STZ-Induced Model of Type-I Diabetes
STZ-induced model of type-I diabetes has been validated for preclinical stroke and
related post-thrombolysis HT-studies [16,17]. It was performed as reported elsewhere [16]
but with slight modifications using 6 days STZ-injection once daily. Mice (10 ± 1-wks old;
total 100 mice) were fasted overnight and injected with 100 mg/kgbwt STZ intraperitoneal
(IP; Sigma-Aldrich Chemicals, St. Louis, MO, USA) on day 1. The following consecutive
5 days, STZ was given at 50 mg/kgbwt IP-dose once daily. This ensured induction of
diabetes in almost all mice except 2 of them. After 3 weeks from the last STZ-injection
and prior to using them for stroke experiments (13 ± 1-wks old), blood glucose level was
measured with a commercial glucometer (Freestyle, Abbott Diabetes Care, Al-Ameda, CA,
USA) as per the manufacturer’s protocol. Mice (n = 98 mice in total) with varying blood
glucose levels ranging between 280–400 mg/dL were considered as diabetic, while the
2 mice with <280 mg/dL blood glucose were excluded from the study protocol.
2.3. BP-Measurement with Tail-Cuff
In Experiment I, multichannel MC4000 tail-cuff instrument (Hatteras Instruments,
Cary, NC, USA) for BP-measurement was used as per the manufacturer’s manual and
instructions. Briefly, after confirming the induction of diabetes at 3 weeks following STZinjection, mice (n = 14 mice) were acclimatized with the instrument for 5 consecutive days
(10 cycles of tail-cuff/day × 3 trials). On the day of measurement, mice were randomized
to 2 sets (n = 7 mice/set); either IV-route or Nebulization-route sets. On day 6, each
set was treated with their respective vehicles (either 200 µL of IV-saline as vehicle for
IV-GSNO baseline control BP-data or 1 mL saline nebulized for 10 min as vehicle for
GSNO-nebulization baseline control data). After 20 min of vehicle treatment, BP (systolic,
diastolic, and mean arterial pressure (MAP)) was recorded and presented as the control
baseline data. Next, on day 7, similar experiment was repeated for each set with either
IV-GSNO (1 mg/kgbwt in 200 µL saline) or GSNO-Nebulization (200 µg/kgbwt in 1 mL
saline for 10 min), and the BP was recorded and compared as the paired data with the
corresponding vehicle-treated baseline data sets. Finally, both sets of mice were humanely
euthanized but not included and used further in stroke experiments.
2.4. Modified IVT-Responsive Photothrombotic (PT)-Model of Stroke
Modified PT-stroke model which produces fibrin-rich clot was adopted from elsewhere [18], but with significant modifications such as lateral-side surgical approach without
craniotomy, laser-beam source, and route of injection. Briefly, mice were anesthetized with
isoflurane (1.5–2% mixed with room air) using a low-flow gas anesthesia system (Somnosuite, Kent Scientific, Torrington, CT, USA). Mice were then transferred to a stereotaxic
frame integrated with an angle device (Stoelting Co, Wood Dale, IL, USA) and a 532 nm
laser source (4.5 mW; beam diameter 2.5–3 mm; ThorLabs, Newton, NJ, USA). The head
was rotated to face right side up, hair was shaved, the temporal muscles under the skin
were blunt dissected and the skull-bone above the zygomatic arc was exposed. An admixture of thrombin and Rose Bengal (RB) dye (80 U/kgbwt and 50 mg/kgbwt, respectively,
in 200 µL of 1× sterile saline; Sigma) was then IV-injected via the tail vein. Using the laser
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light, the distal trunk of middle cerebral artery (MCA) was visualized underneath the bone
and the laser was lowered down to the skull bone, illuminated, and exposed for 15 min.
Thrombotic occlusion of the distal lateral trunk of MCA was confirmed with the LDF (>70%
drop in focal CBF). Finally, wound was closed carefully using 3M VetBond tissue glue
(Santa Cruz Biotechnology, Santa Cruz, CA, USA). Mice were then transferred to a clean
warm cage for recovery (4-mice/cage) and provided food and water freely.
2.5. Treatments and Therapies after Stroke
From each block (4-stroked mice/cage), mice were block-randomized to different
treatments as needed for two groups in each experiment. In all 3 experiments, Aeroneb
lab nebulizer unit small VMD integrated to a nose-cone animal holder and Somnosuite
(Kent Scientific), was used for nebulization (1 mL volume for 10 min) in conscious mice
as per the vendor’s instructions. Either vehicle (1× sterile saline, +Veh group) or GSNO
(Sigma; 100 µg/kgbwt in saline × 2 doses at 2 h and 6 h post-stroke) were nebulized as
needed for different groups. For IVT (+IVT groups in Experiments III and IV), recombinant
tissue plasminogen activator (rt-PA; Altepase, Genentech, San Francisco, CA, USA) was
used as reported earlier by us [19]; however, since this PT-stroke is a model of smaller clot
formation and injury, we used rt-PA at a dose of 5 mg/kgbwt. In our hands, this dose of
IVT beyond 3 h post-stroke does not cause unexpected higher mortality, as often seen in
diabetic stroke, but results in effective thrombolysis and shows signs of HT, which serves
the purpose of this study.
2.6. Laser Doppler Flowmetry (LDF) and Laser Speckle Contrast Analysis (LASCA) Imaging
LDF (Perimed (Sweden) Inc., Las Vegas, NV, USA) for focal CBF in Experiment II–IV,
and LASCA imaging (RFLSI-III, RWD Life Sciences, San Diego, CA) in Experiment II
for global relative CBF (% change) were performed as reported by us [19,20]. Briefly, an
LDF-probe (PH407, Perimed) was inserted into the LDF probe holder (PH07-6, Perimed;
pre-fixed at the stereotaxic coordinates, AP: 2 mm and ML: 3 mm with respect to bregma).
The LDF perfusion signal (in arbitrary unit, AU) was recorded prior to initiating the
induction of stroke and 10 min after the completion of laser exposure to confirm the
induction of stroke. In brief, for LASCA imaging at 24 h post-stroke, anesthetized mice
were maintained at 37 ± 0.5 ◦ C body temperature, and the recording was performed on an
exposed clean skull. The acquired perfusion videos were analyzed for % CBF changes in
the ipsilateral ischemic hemisphere normalized to the uninjured contralateral hemisphere.
2.7. Behavioral Tests
For all 3 behavioral tests, mice were pre-trained for 3 days (3 trials/day) prior to
the stroke surgery. These tests have been recommended to determine subtle changes in
behavioral outcomes following stroke models of smaller injury [19–23]. In Experiment II,
at 48 h post-stroke and prior to sacrifice, the motor balance function of mice was assessed
with the balance beam walk test (BWT). Briefly, pre-trained stroke mice were individually
tested to walk on a 100 cm long beam with 3 trials × 5 min interval between each trial.
BWT performance of each mouse was quantified by measuring the time taken (in seconds,
s) by the mouse to traverse the beam, and the mean value of 3 trials was calculated and
presented as the BWT outcome measure [21,22]. In Experiment IV, adhesive tape test (ATT)
as the somatosensory functional outcome at 24 h post-stroke was performed as reported by
us [19], prior to sacrificing both sets of groups for the estimation of Evan’s blue (EB) content
for blood-brain barrier (BBB) leakage and hemoglobin (Hb) content as the marker of HT.
As reported by us [19], higher time (in second, s) taken by the mouse to remove the tactile
stimuli (adhesive tape) from the paw indicates a poorer outcome and vice versa in this ATT
method. In addition, hanging wire test (HWT) for the muscular strength and coordination
in Experiment IV also was performed as reported elsewhere [21]. Briefly, pre-trained
stroked mice were gently encouraged to hold a hanging wire with both forelimbs. The
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fall latency (in second, s) was recorded for 3 trials × 5 min interval between trials for each
mouse, and the mean value was calculated to present as the outcome measure of the HWT.
2.8. 2,3,5-Triphenyltetrazolium Chloride (TTC) Staining for Infarct Volume Analysis
TTC-stain differentiates between metabolically active (live or penumbra) and inactive
(dead or core) tissues after stroke as reported by us [19]. In Experiment II, it was performed
to measure the infarct/stroke injury size at 48 h post-stroke [19].
2.9. Measurement of Brain Tissue Oxygen (PbtO2) with Fluorescence Quenching Optic Probes
Optical measurement of PbtO2 was performed at 6.5 h post-stroke and after the 2nd
dose nebulization of GSNO (terminal Experiment III). The optical measurement technique
for O2 carries many advantages over the classical electrochemical method, such as that no
oxygen consumption occurs during the optical method. The polymer membrane of the
probe, loaded with a luminescent dye, glows in the absence of oxygen when exposed to the
light passing through the probe. In response to collision with available oxygen molecules,
luminescence quenching occurs; thus, higher oxygen concentration results in the lesser
back transmittance of the light to the detector and vice versa. Briefly, for in vivo optical
recording of PbtO2, an optic fiber (OXR50, tip diameter 50–70 µm (patented technology of
Pyro Science GmbH, Aachen-Germany); Ohio Lumex, Solon, OH, USA) was inserted into
the brain (stereotaxic coordinates, AP: 0.5 mm and ML: 1.5 mm with respect to bregma)
about 1.5 mm deep (dorso-ventral, DL) and immediately retracted back ~0.5 mm to create
a void space. The pre-calibrated signal output (in mm of Hg) was stabilized for ~2–4 min
and finally recorded and averaged for the next 3 min duration.
2.10. Measurement of BBB-Leakage and Hemorrhagic Transformation (HT)
Changes in BBB-integrity and HT following late-IVT therapy (3.5 h post-stroke) and
their modulation with GSNO-nebulization as an adjunct therapy was performed as reported earlier by us with certain modifications [19,24]. Briefly, in Experiment IV, 100 µL of
EB-dye (Sigma; 5% solution in sterile 1× saline) was IV-injected at 6 h post-stroke. Mice
were sacrificed following neurobehavioral tests (ATT and HWT) at 24 h post-stroke. Mice
were perfused with chilled 1× PBS, ipsilateral hemispheres were harvested, weighed,
homogenized in 650 µL of 1× PBS and sonicated. An equal volume of 50% trichloroacetic
acid (TCA, Sigma) was added and incubated overnight in the dark at 4 ◦ C. Finally, samples
were centrifuged (30 min, 15,000 rpm, 4 ◦ C), supernatants were collected, the absorbance of
EB-dye was measured at 610 nm and quantified according to a standard curve. The results
were presented as µg of EB/g of tissue. For HT volume quantitation, Hb-content (in µL)
was estimated as reported by us and others [20,25]. Briefly, 20 µL of clear supernatant obtained from the ipsilateral tissue homogenate was mixed with 80 µL of Drabkin’s Reagent
(Sigma) in triplicates in a 96-well plate. The absorbance after 15 min was read at 540 nm.
Hb-content in the brain samples were calculated from a standard curve using the mean
absorbance for each sample.
2.11. Data Collection and Statistical Analysis
Paired t-test was used to compare the baseline vehicle treated control BP data to that
of the corresponding GSNO-treated data in Experiment I (n = 7). For stroke experiments
(II–IV), based on our prior experiences for changes in infarct size as the primary outcomes
at 48 h, we anticipated at least 20% reduction in the infarct volume with up to 20% standard
deviation (SD). Therefore, we set the sample size to achieve at least 80% power at 5% level
of significance to detect main effects. In each experiment, mice were block randomized in
blocks of 4 mice/cage for the two groups. Data collection and analyses were blinded to
the investigators. Quantitative data are presented as mean ± SD, statistical analysis was
performed with at least n ≥ 8 and a p-value < 0.05 was considered statistically significant.
Unpaired t-test was performed to determine the statistical significance, and wherever needed,
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cance was determined at p < 0.05 and using an unpaired t‐test. No mortalities were observed by 24 h post‐stroke at the time
procedure
as rarely as
seen
in this
mini-infarct
model ofmodel
PT-stroke.
of LSCI procedure
rarely
seen
in this mini‐infarct
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3.3. Nebulization of Low‐Dose GSNO Enhances Post‐Thrombolysis Brain Tissue Oxygenation
3.3.
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Mice
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Thrombolytic recanalization of an occluded artery may not necessarily translate into
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an optimal microvascular perfusion and enhanced PbtO2, the master requisite to treat an
ischemic brain.
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PbtO2 following
evident
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Figure
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with with
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PbtO2
following thrombolysis
thrombolysisininstroke.
stroke.AsAs
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from
Figure
“+GSNO
enhanced
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post‐stroke
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“+Veh
with
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IVT” enhanced the PbtO2 at 6.5 h post-stroke significantly as compared to “+Veh with
(50.8
±
9.3
mm
Hg
vs.
41.7
±
8.8
mm
Hg,
respectively,
p
<
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Our
data
demonstrate
IVT” (50.8 ± 9.3 mm Hg vs. 41.7 ± 8.8 mm Hg, respectively, p < 0.0379). Our data
that late‐IVT therapy
in diabetic
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with
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further
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however, a combination with GSNO further enhances the restoration of PbtO2 following
lysisthrombolysis
in diabetic mice.
late
in diabetic mice.
3.4. Nebulized GSNO in Combination with Late Thrombolysis Augments Behavioral Outcomes
GSNO alone has been reported to improve behavioral outcomes following mechanical
occlusion-reperfusion in rodents; however, the potential benefits of GSNO-therapy on
behavioral outcomes remain unknown in a setting of thrombotic occlusion and in combination with late-IVT therapy. Therefore, in a larger set of mice (n = 17–20 mice/group),
we investigated the benefits of GSNO in combination with late-IVT therapy in improving
behavioral outcomes (Figure 5A,B). As evident, “+GSNO with IVT” compared to “+Veh
with IVT” significantly enhanced the somatosensory functional outcomes as tested with
ATT (36.8 ± 8.8 s vs. 46.1 ± 9.5 s, p < 0.0042), and muscular strength and coordination to
grip (motor coordination) as determined with HWT (40.45 ± 8.2 s vs. 34.5 46.1 ± 5.9 s,
p < 0.0164). Thus, our data demonstrate that nebulized GSNO supplement with late-IVT
therapy is beneficial in improving functional outcomes.
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3.4. Nebulized GSNO in Combination with Late Thrombolysis Augments Behavioral Outcomes
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with
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augmented
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control group but also increased the HT (darker patches of blood under the EB-stain). On
the other hand, as it can be seen, this was collectively attenuated in the +GSNO group with
IVT. Furthermore, quantification of EB- and Hb-contents demonstrated that “+GSNO with
IVT” significantly prevented the EB-content (p < 0.0363) and Hb-content (p < 0.0006) as
compared to the “+Veh with IVT” controls (Figure 6B,C), thus evidencing that low-dose
GSNO nebulization attenuates the detrimental effects of late-IVT on the BBB integrity and
reduces the risk of HT in diabetic mice.
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left without All
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all surviving mice of both sets were euthanized for the quantification of EB‐ and Hb‐contents.
Statistical significance was determined at p < 0.05 and using an unpaired t-test. Following behavioral outcome measures, all
surviving mice of both sets were euthanized for the quantification of EB- and Hb-contents.

3.5. Low Dose GSNO Nebulization Attenuates Detrimental Effects of Late Thrombolysis in
Diabetic Mice

The FDA approves and recommends the use of IVT‐therapy in stroke within 3 h post‐
ictus beyond which IVT could augment the BBB‐leakage and HT itself. Moreover, pre‐
existing diabetes exacerbates the risk of BBB‐disruption and HT after stroke [16,17], par‐
ticularly in the setting of late‐IVT treatment, thereby shortening the safer thrombolytic
window and limiting the benefits of IVT‐therapy in diabetic stroke. Therefore, in view of
the critical translational relevance, we next evaluated whether GSNO would abolish or
attenuate BBB‐disruption and HT following late‐IVT in diabetic mice (Figure 6A–C). As
evident from the representative images (Figure 6A), late‐IVT at 3.5 h post‐stroke not only
augmented the BBB‐leakage as determined by more intense appearance of EB‐stain in
+Veh control group but also increased the HT (darker patches of blood under the EB‐
stain). On the other hand, as it can be seen, this was collectively attenuated in the +GSNO
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group with IVT. Furthermore, quantification of EB‐ and Hb‐contents demonstrated that
“+GSNO with IVT” significantly prevented the EB‐content (p < 0.0363) and Hb‐content (p
< 0.0006) as compared to the “+Veh with IVT” controls (Figure 6B,C), thus evidencing
that
11 of
14
low‐dose GSNO nebulization attenuates the detrimental effects of late‐IVT on the BBB
integrity and reduces the risk of HT in diabetic mice.
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The benefits of BP-lowering in stroke remains debated, although reduction of systolic
BP prior to IVT-therapy could be beneficial in subjects with extreme hypertension [26]. On
the other hand, significant reduction of BP, even to the lower levels of the hypertensive
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range, could be detrimental in stroke patients [27]. As evident from our data (Figure 1), a
higher dose of IV-GSNO had a significant effect on BP-lowering (Figure 1A) which likely
resulted in frequent HT, as seen by us (Figure 6), and exacerbated stroke injury, as reported
by others [15]. On the other hand, low-dose nebulization of GSNO remains well-tolerated
and did not alter the BP (Figure 1B). Since nebulization, as the route of administration, bears
higher translational applicability in clinical stroke settings and allows enhanced control
for safer drug delivery, we found it encouraging to test in thrombotic stroke with diabetes.
When tested, low-dose GSNO-nebulization alone enhanced the CBF, improved behavioral
outcomes and attenuated the progression of stroke injury in diabetic mice without altering
the BP (Figures 1–3). Moreover, in combination with the thrombolytic reperfusion therapy,
GSNO-nebulization did not cause any adverse effects but diminished the unwanted effects
of late-IVT in diabetic mice, likely via enhanced re-oxygenation in early hours (Figures 4–6),
which eventually translated into improved behavioral outcomes. These findings indicate
that the nebulization of GSNO hits the key therapeutic goals required to treat a stroke in
early hours.
Successful reperfusion in major vessels and restoration of CBF therein do not necessarily guarantee the restoration of microvascular perfusion, eventually responsible for
reinstating the oxygenation of brain tissue [28–30]. Therefore, the development of affordable field therapies in stroke, which will be conveniently accessible to paramedics and
safer to use at primary care centers, during transportation in ambulance and in EDs, is
desperately needed in developing countries such as the KSA, with limited healthcare
infrastructure. Most importantly, if field therapies are effective at enhancing collateral
microcirculation and PbtO2 in the early hours after stroke, this will have the benefits of
reducing mortalities, the severity of long-term disabilities and associated healthcare costs.
Therefore, in summary, our findings in this report draw attention to further validate GSNOtherapy in different models of thromboembolic stroke with and without comorbidities
in aged animals of both sexes to better represent a clinical stroke scenario. Moreover,
NO-therapy is being actively tested worldwide in severe COVID-19 patients in need of
exogenous oxygen support (NICOR trial: NCT04476992; and NCT04383002), and different modes of NO-delivery in mild-moderate COVID-19 patients, such as NO-inhalation
(NCT04305457), NO-releasing solutions (NOCOVID trial and NCT04337918) and NOlozenges (NCT04601077) etc. Since COVID-19 patients remain at higher risk of thrombotic
stroke due to cytokine storm and resultant acute respiratory disorder syndrome (ARDS),
future preclinical testing of GSNO as a NO-therapy is also encouraged in preclinical models
of COVID-19 and/or ARDS accompanying stroke.
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